This database links over 4,000 consumer brands to health effects from Material Safety Data Sheets (MSDS) provided by the manufacturers and allows scientists and consumers to research products based on chemical ingredients.

The Household Products Database of the National Library of Medicine is based on the Consumer Product Information Database ©2001-2013 by DeLima Associates. All rights reserved.

The Total Product Life Cycle (TPLC) database integrates premarket and postmarket data about medical devices. It includes information pulled from CDRH databases including Premarket Approvals (PMA), Premarket Notifications (510[k]), Adverse Events, and Recalls. You can search the TPLC database by device name or procode to receive a full report about a particular product line.

The data below contains newly reported, active covered outpatient drugs which were reported by participating drug manufacturers since the last quarterly update of the Drug Products in the Medicaid Drug Rebate Program (MDRP) database.

This database contains product names and associated information developed by the Center for all products, both medical and non-medical, which emit radiation. It includes a three letter product code, a descriptor for radiation type, applicable performance standard(s), and a definition for the code.

NOTE: As of 12/17/2024, this dataset is no longer updated. Please use ASPR Treatments Locator. This dataset displays pharmacies, clinics, and other locations with safe and effective COVID-19 medications. These medications require a prescription from a healthcare provider. Some locations, known as Test to Treat sites, give you the option to get tested, get assessed by a healthcare provider, and receive treatment – all in one visit. COVID-19 medications may be available at additional locations that are not shown in this dataset. The locations displayed have either self-attested they have inventory of Paxlovid (nirmatrelvir packaged with ritonavir), Lagevrio (molnupiravir), or Veklury (Remdesivir) within at least the last two months and/or reported participation in the Paxlovid Patient Assistance Program. Sites that have not reported in the last two weeks display a notification, "Inventory has not been reported in the last 2 weeks. Please contact the provider to make sure the product is available." Outpatient COVID-19 medications may be available at additional locations not listed on this website. All therapeutics identified in the locator not approved by the FDA must be used in alignment with the terms of the respective product’s Emergency Use Authorization. Visit COVID-19 Treatments and Therapeutics for more information on all treatment options. This website identifies sites that have commercially purchased inventory of COVID-19 treatments and, in some cases, may identify sites that have remaining, no-cost U.S. government distributed supply. Some sites may charge for services not covered by insurance. Some sites may offer telehealth services. This website is intended for informational purposes only and does not serve as an endorsement or recommendation for use of any of the locations listed on the sites. Clarification for DoD Facilities: Those individuals eligible for care in an MTF include Active Duty Service Members (ADSMs), covered beneficiaries enrolled in TRICARE Prime or Select, including TRICARE Reserve Select (TRS), TRICARE Retired Reserve (TRR) and TRICARE Young Adult (TYA) participants, TRICARE for Life beneficiaries, and individuals otherwise entitled by law to MTF care (e.g., regular retired members and their dependents who are not enrolled in TRICARE but who are otherwise eligible for MTF space-available care, certain foreign military members and their families registered in DEERS, and others).

The data below contains newly reported, active covered outpatient drugs which were reported by participating drug manufacturers since the last quarterly update of the Drug Products in the Medicaid Drug Rebate Program (MDRP) database.

According to 21 CFR 210.3(b)(8), an inactive ingredient is any component of a drug product other than the active ingredient. Only inactive ingredients in the final dosage forms of drug products are in this database.

NOTE: This dataset is no longer updated as of 1/31/2024. Please use COVID-19 Treatments. Data Information and Disclaimers The locations displayed above have received an order of Paxlovid or Lagevrio (molnupiravir) in the last two months and/or have reported availability of the oral antiviral medications within the last two weeks. Those sites that have not reported in the last two weeks display a notification with the site details, "Inventory has not been reported in the last 2 weeks. Please contact the provider to make sure the product is available." All therapeutics identified in the locator must be used in alignment with the terms of the respective product’s EUA. Data displayed on this page is for informational purposes only. The data on this page is for locations with the oral antivirals Pfizer's Paxlovid and Merck's Lagevrio (molnupiravir). Visit COVID-19 Treatments and Therapeutics for more information on all treatment options. The medication is provided at no cost. Some sites may charge for services not covered by insurance. Some sites may offer telehealth services. This website is intended for informational purposes only and does not serve as an endorsement or recommendation for use of any of the locations listed on the sites. Clarification for DoD Facilities: Those individuals eligible for care in an MTF include Active Duty Service Members (ADSMs), covered beneficiaries enrolled in TRICARE Prime or Select, including TRICARE Reserve Select (TRS), TRICARE Retired Reserve (TRR) and TRICARE Young Adult (TYA) participants, TRICARE for Life beneficiaries, and individuals otherwise entitled by law to MTF care (e.g., regular retired members and their dependents who are not enrolled in TRICARE but who are otherwise eligible for MTF space-available care, certain foreign military members and their families registered in DEERS, and others).

The National Health Related Items Code (NHRIC) is a system for identification and numbering of marketed device packages that is compatible with other numbering systems such as the National Drug Code (NDC) or Universal Product Code (UPC). Those manufacturers who desire to use the NHRIC number for unique product identification may apply to FDA for a labeler code. This database contains NHRIC data retrieved from records that date back 20 years.

For a drug product that does not have a dissolution test method in the United States Pharmacopeia (USP), the FDA Dissolution Methods Database provides information on dissolution methods presently recommended by the Division of Bioequivalence, Office of Generic Drugs.

The FDA Peanut-Containing Product Recall widget allows you to browse the Food and Drug Administration (FDA) database of peanut butter and peanut-containing products subject to recall. This database makes it easier for you to determine whether any of the products you have at home are subject to recent recalls, and will be updated as new information becomes available.

The FDA shall publish in a format that is understandable and not misleading to a lay person, and place on public display, a list of 93 harmful and potentially harmful constituents in each tobacco product and smoke established under section 904(e) of the TCA. CTP has determined the best means to display the data is web-based on FDA.GOV. The HPHC back-end database and template for industry will be created in a future release of eSubmissions. The scope of this project is to: Phase 1 (Current POP): 1) build a website to support the display of the HPHC constituents, 2) allow the user to access educational information about the health effects of the chemicals; Phase 2 (next POP): 1) allow users of the website to perform a search by brand and sub-brand, 2) display a report on the HPHCs contained in that tobacco product, and 3) create an admin module to allow for an import of HPHC data via an Excel spreadsheet and to update the list of constituents.

The Medicare Electronic Health Record (EHR) Incentive Program provides incentives to eligible clinicians and hospitals to adopt electronic health records. This dataset combines meaningful use attestations from the Medicare EHR Incentive Program and certified health IT product data from the ONC Certified Health IT Product List (CHPL) to identify the unique vendors, products, and product types of each certified health IT product used to attest to meaningful use. The dataset also includes important provider-specific data, related to the provider's participation and status in the program, unique provider identifiers, and other characteristics unique to each provider, like geography and provider type.

Contains data for FDA peanut product recalls since January 2009.

The Adverse Event Reporting System (AERS) is a computerized information database designed to support the FDA's post-marketing safety surveillance program for all approved drug and therapeutic biologic products. The FDA uses AERS to monitor for new adverse events and medication errors that might occur with these marketed products. Reporting of adverse events from the point of care is voluntary in the United States. FDA receives some adverse event and medication error reports directly from health care professionals (such as physicians, pharmacists, nurses and others) and consumers (such as patients, family members, lawyers and others). Healthcare professionals and consumers may also report these events to the products' manufacturers. If a manufacturer receives an adverse event report, it is required to send the report to FDA as specified by regulations. The files listed on this page contain raw data extracted from the AERS database for the indicated time ranges and are not cumulative. Users of these files need to be familiar with creation of relational databases using applications such as ORACLE, Microsoft Office Access, MySQL and IBM DB2 or the use of ASCII files with SAS analytic tools. A simple search of AERS data cannot be performed with these files by persons who are not familiar with creation of relational databases.

This list includes products subject to recall since September 2010 related to infant formula distributed by Abbott. This list will be updated with publicly available information as received. The information is current as of the date indicated. If we learn that any information is not accurate, we will revise the list as soon as possible. When available, this database also includes photos of recalled products that have been voluntarily submitted by recalling firms to the FDA to assist the public in identifying those products that are subject to recall.

Information about FDA-approved brand name and generic prescription and over-the-counter human drugs and biological therapeutic products. Drugs@FDA includes most of the drug products approved since 1939. The majority of patient information, labels, approval letters, reviews, and other information are available for drug products approved since 1998.

This list is intended to alert consumers about Web sites that are or were illegally marketing unapproved, uncleared, or unauthorized products in relation to the 2009 H1N1 Flu Virus (sometimes referred to as the 'swine flu' virus).

NCBI creates a variety of educational products including courses, workshops, webinars, training materials and documentation. NCBI educational events are free and open to everyone. All NCBI educational materials are available for anyone to re-use and distribute